Insights & Resources – COD Research – Designing Therapies For Future

Medical Affairs

CT Quality Assurance

Clinical Services

Biometrics

Transforming Complexity into Success: A Large-Scale Global Phase III Biosimilar Dermatology Trial

Strategic Planning for Patient Recruitment

Pulmonary Disease Introduction: Prevalence, Causes, Prevention & Treatment

EMA
FDA
MHRA

EMA starts review of sodium oxybate in alcohol dependence
Source: EMA Published on 2025-06-20
Referral: Sodium oxybate-containing syrup and oral solution for alcohol dependence, sodium oxybate Article 31 referrals Procedure started
Source: EMA Published on 2025-06-20
Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine,tozinameran,riltozinameran and tozinameran,famtozinameran and tozinameran,raxtozinameran, Date of authorisation: 21/12/2020, Revision: 54, Status: Authorised
Source: EMA Published on 2025-06-20
Opinion/decision on a Paediatric investigation plan (PIP): Brukinsa, zanubrutinib, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Blood and lymphatic system disorders, PIP number: P/0226/2024
Source: EMA Published on 2025-06-20
EMEA-003613-PIP01-24
Source: EMA Published on 2025-06-20
EMEA-003613-PIP01-24
Source: EMA Published on 2025-06-20

Read More